Advanced Filters
noise

Junggu, Korea, Republic of Clinical Trials

A listing of Junggu, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 1,384 clinical trials

ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74

The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in the Bacillus Calmette-Guérin (BCG)-vaccinated older adults aged 55 to 74 with negative or positive result on the QuantiFERON-TB (QFT) …

55 - 74 years of age All Phase 1
Y Young Nam Youn, MD

The Characteristics and Treatment Mechanism of Vascular Grafts in Elderly Patients With CAOD Through Single-cell Transcriptome Analysis

This study aims to establish a cardiovascular biobank using vascular grafts obtained from participants with coronary artery occlusive disease (CAOD). Through genomic and transcriptomic analyses, the study seeks to characterize the biological features of the vascular grafts and identify potential therapeutic targets and mechanisms related to vascular remodeling and stiffness.

19 - 100 years of age All Phase N/A

The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients

Clinical Study to Evaluate the Efficacy and Safety of Atock Dry Syrup with Acute bronchial Patients

6 - 11 years of age All Phase 4

Safety of DNP007 in Healthy Subjects

This clinical trial evaluated the safety, tolerability, pharmacokinetic properties, and immunogenicity of DNP007 when administered as a single dose. Since this is a phase 1 study for exploratory evaluation, to the extent that it meets the study objectives, In order to proceed with the minimum number of subjects, a total …

19 - 55 years of age Male Phase 1
C Cheol Min Shin, M.D., Ph.D.

Cohort Study for Gastric MALT Lymphoma

The goal of this observational study is to establish clinical data and tissue repository in patients with gastric MALT lymphoma and controls. Participants will be asked to provide clinical information and various tissues (saliva, gastric mucosa, and feces).

18 - 75 years of age All Phase N/A

Efficacy and Safety of Kefir Whey Postbiotics

Research staff conduct screening tests only on applicants who provide written consent and select research subjects who meet the selection criteria. Study subjects will visit for the first time within 4 weeks from the screening visit to reexamine the suitability of the study subject selection/exclusion criteria and then be enrolled …

40 years of age All Phase N/A

Case Studies of Patients Who Had Experienced Near Death Experience

An prospective observational study to interview patients who had near death experiences among those who had received intensive care unit intervention during admission in hematology ward.

19 years of age All Phase N/A
Y Young Chul Jung, MD

Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers

This study aims to evaluate and compare the degree of alcohol reduction between high-risk drinkers who use a motivational interviewing-based conversational agent (chatbot) application for four weeks and those in the control group who do not use the application, in order to verify its clinical effectiveness.

19 - 59 years of age All Phase N/A
J Jeong Il Yu, MD, PhD

PULSAR in Systemic Therapy for Pancreatic Cancer

Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection. A substantial proportion of patients present with locally advanced, unresectable disease at the time of diagnosis, making intensive systemic therapy the current standard of care. For …

19 years of age All Phase 2
M Myung-Ju Ahn, M.D.

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

As the 3rd generation, EGFR TKI has become a standard treatment option for the 1st line therapy in EGFR mutated patients, the necessity for evaluating resistant mechanism to determine the matched subsequent therapeutic option has been highlighted. From the 1st line Osimertinib treatment, the heterogenous resistance mechanism has been observed …

19 years of age All Phase 2

Simplify language using AI